4.5 Article

Functional evaluation of epilepsy-associated KCNT1 variants in multiple cellular systems reveals a predominant gain of function impact on channel properties

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism

Francesco Miceli et al.

Summary: This study investigated the phenotypes and functional properties associated with KCNQ2 missense variants R144W, R144Q, and R144G. The results revealed that these variants were correlated with developmental delay, language impairment, epilepsy, and autistic features. Amitriptyline was found to block channels carrying the R144Q variant.

EBIOMEDICINE (2022)

Article Clinical Neurology

Somatic Mosaic Pathogenic Variant Gradient Detected in Trace Brain Tissue From Stereo-EEG Depth Electrodes

Zimeng Ye et al.

Summary: Using trace tissue from explanted stereoelectroencephalography (SEEG) electrodes, we successfully identified a mosaic gradient for a brain pathogenic variant. The mosaic gradient correlated strongly with the epileptogenic region, providing important information for clinical diagnosis and treatment.

NEUROLOGY (2022)

Article Medicine, Research & Experimental

Antisense oligonucleotide therapy for KCNT1 encephalopathy

Lisseth Estefania Burbano et al.

Summary: This study demonstrates the potential of ASO-based gene silencing as a promising therapeutic approach in KCNT1-associated epilepsies. ASO treatment significantly reduced seizure frequency, improved behavioral abnormalities, and extended overall survival in the mouse model.

JCI INSIGHT (2022)

Article Chemistry, Medicinal

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series

Andrew M. Griffin et al.

Summary: Variants in the KCNT1 gene lead to neurological disorders like epilepsy without effective treatments. Researchers have developed a novel oxadiazole compound, 31, which can reduce seizures in a mouse model of KCNT1-associated disease.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

Article Clinical Neurology

KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum

Claudia M. Bonardi et al.

Summary: Variants in the KCNT1 gene are associated with a range of epilepsies and neurodevelopmental disorders. This study provides a comprehensive overview of the phenotypic and genotypic spectrum of KCNT1 mutation-related epileptic disorders in a cohort of 248 individuals, identifying four main phenotypic groups and emphasizing the role of this gene in early onset developmental and epileptic encephalopathies as well as focal epilepsies.

BRAIN (2021)

Article Clinical Neurology

SCN1A gain of function in early infantile encephalopathy

Geza Berecki et al.

ANNALS OF NEUROLOGY (2019)

Article Biochemistry & Molecular Biology

Structural Titration of Slo2.2, a Na+-Dependent K+ Channel

Richard K. Hite et al.

Article Neurosciences

Characterization of two de novo KCNT1 mutations in children with malignant migrating partial seizures in infancy

Francesca Rizzo et al.

MOLECULAR AND CELLULAR NEUROSCIENCE (2016)

Article Clinical Neurology

KCNT1 Gain of Function in 2 Epilepsy Phenotypes is Reversed by Quinidine

Carol J. Milligan et al.

ANNALS OF NEUROLOGY (2014)